Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Statistics

Total Valuation

Cell Biotech has a market cap or net worth of KRW 88.63 billion. The enterprise value is 3.26 billion.

Market Cap	88.63B
Enterprise Value	3.26B

Important Dates

The last earnings date was Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Cell Biotech has 6.84 million shares outstanding.

Current Share Class	6.84M
Shares Outstanding	6.84M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	34.49%
Owned by Institutions (%)	8.79%
Float	4.48M

Valuation Ratios

The trailing PE ratio is 8.77.

PE Ratio	8.77
Forward PE	n/a
PS Ratio	1.87
PB Ratio	0.72
P/TBV Ratio	0.73
P/FCF Ratio	9.10
P/OCF Ratio	8.09
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.34, with an EV/FCF ratio of 0.34.

EV / Earnings	0.32
EV / Sales	0.07
EV / EBITDA	0.34
EV / EBIT	0.56
EV / FCF	0.34

Financial Position

The company has a current ratio of 16.37, with a Debt / Equity ratio of 0.01.

Current Ratio	16.37
Quick Ratio	15.38
Debt / Equity	0.01
Debt / EBITDA	0.08
Debt / FCF	0.08
Interest Coverage	124.16

Financial Efficiency

Return on equity (ROE) is 8.45% and return on invested capital (ROIC) is 3.03%.

Return on Equity (ROE)	8.45%
Return on Assets (ROA)	2.91%
Return on Invested Capital (ROIC)	3.03%
Return on Capital Employed (ROCE)	4.74%
Revenue Per Employee	469.86M
Profits Per Employee	100.12M
Employee Count	106
Asset Turnover	0.38
Inventory Turnover	2.80

Taxes

Income Tax	-686.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.96% in the last 52 weeks. The beta is 0.63, so Cell Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	-7.96%
50-Day Moving Average	13,207.40
200-Day Moving Average	13,399.70
Relative Strength Index (RSI)	47.66
Average Volume (20 Days)	7,890

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cell Biotech had revenue of KRW 47.46 billion and earned 10.11 billion in profits. Earnings per share was 1,477.23.

Revenue	47.46B
Gross Profit	34.14B
Operating Income	5.86B
Pretax Income	9.43B
Net Income	10.11B
EBITDA	9.59B
EBIT	5.86B
Earnings Per Share (EPS)	1,477.23

Balance Sheet

The company has 86.10 billion in cash and 732.99 million in debt, giving a net cash position of 85.37 billion or 12,473.20 per share.

Cash & Cash Equivalents	86.10B
Total Debt	732.99M
Net Cash	85.37B
Net Cash Per Share	12,473.20
Equity (Book Value)	123.49B
Book Value Per Share	18,044.04
Working Capital	91.40B

Cash Flow

In the last 12 months, operating cash flow was 10.96 billion and capital expenditures -1.22 billion, giving a free cash flow of 9.74 billion.

Operating Cash Flow	10.96B
Capital Expenditures	-1.22B
Free Cash Flow	9.74B
FCF Per Share	1,422.63

Margins

Gross margin is 71.94%, with operating and profit margins of 12.35% and 21.31%.

Gross Margin	71.94%
Operating Margin	12.35%
Pretax Margin	19.86%
Profit Margin	21.31%
EBITDA Margin	20.20%
EBIT Margin	12.35%
FCF Margin	20.52%

Dividends & Yields

This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.50%.

Dividend Per Share	450.00
Dividend Yield	3.50%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	30.46%
Buyback Yield	n/a
Shareholder Yield	3.50%
Earnings Yield	11.41%
FCF Yield	10.99%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cell Biotech has an Altman Z-Score of 11.98 and a Piotroski F-Score of 6.

Altman Z-Score	11.98
Piotroski F-Score	6